Salvé Technologies

Vision: We are building a high-performance computing powered ML/AI bioengineering platform to design, model and test novel viral-mediated gene therapies for time and cost-efficient in silico R&D. Over 5% of newborns suffer from a genetic disease. These include single gene, polygenic and chromosomal disorders. Many other non-congenital diseases with genetic components are activated by environmental triggers (autoimmune, cancer, tissue injury). Sophisticated gene therapies are a path to curing these diseases and improving quality of life. Current gene therapies are mostly limited to plasmid-based and Adeno-associated virus variants with inefficient response rates and limited use, with some herpes, lenti, and retroviral modalities. Development is slow and expensive. Better viral delivery methods would expand the available gene therapy tool kit to produce better medicines for intractable and incurable diseases. Platform: Biological CAD (or BioCAD) is dawning for the development of protein and nucleic acid biologics, but viruses remain relatively unexplored. Salvé's software platform is specifically tailored to mine, design and test the human virome for new therapeutic modalities, enabling exploration of this therapeutic space in a safe, rapid and cost-effective manner. These modalities would be useful for treating and potentially curing the many inherited and acquired genetic disorders afflicting humanity due to their therapeutic specificity, efficiency and irreversibility. Salvé Technologies will discover novel drug candidates using VirCAD©. VirCAD© will enable the design, simulation and testing of novel viral particles in silico via the following core functions: Bioinformatics: mine public (or private) viromic databases for components. Molecular Modeling: construct novel viral particles from the components. PK/PD Simulation: test how the novel viral particles would access, bind, infect and physiologically alter/be altered by the host tissues of interest.